Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

ASIM V FAROOQ

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1639436777
CMS profile
1093391
Location
CHICAGO, IL

General Payments · PY2018–2024

$210,058.90

  • Reported across 85 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$25,923.06

15 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $8,037.50 4
GlaxoSmithKline, LLC. $5,525.00 3
GENZYME CORPORATION $5,094.00 2
AstraZeneca UK Limited $4,430.25 3
ABBVIE INC. $2,836.31 3

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $2,602.70 3
PY2019 $11,714.44 13
PY2020 $77,272.00 14
PY2021 $35,239.58 12
PY2022 $44,777.75 18
PY2023 $12,529.37 10
PY2024 $25,923.06 15

Payment records · PY2024 (15)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $116.31 04/05/2024 Food and Beverage Undisputed 01/23/2026 1103712225 CMS
ABBVIE INC. $2,040.00 06/05/2024 Consulting Fee Undisputed 01/23/2026 1103134215 CMS
ABBVIE INC. $680.00 11/20/2024 Consulting Fee Undisputed 01/23/2026 1103134217 CMS
Amgen Inc. $964.50 03/25/2024 Consulting Fee Undisputed 01/23/2026 1117551559 CMS
Amgen Inc. $2,411.25 05/24/2024 Consulting Fee Undisputed 01/23/2026 1117551557 CMS
Amgen Inc. $3,054.25 09/25/2024 Consulting Fee Undisputed 01/23/2026 1117551561 CMS
Amgen Inc. $1,607.50 10/16/2024 Consulting Fee Undisputed 01/23/2026 1117551563 CMS
AstraZeneca UK Limited $805.50 08/02/2024 Consulting Fee Undisputed 01/23/2026 1093972490 CMS
AstraZeneca UK Limited $2,685.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1093959551 CMS
AstraZeneca UK Limited $939.75 08/30/2024 Consulting Fee Undisputed 01/23/2026 1094005525 CMS
GENZYME CORPORATION $4,250.00 07/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1139853237 CMS
GENZYME CORPORATION $844.00 07/24/2024 Consulting Fee Undisputed 01/23/2026 1139853239 CMS
GlaxoSmithKline, LLC. $325.00 04/15/2024 Consulting Fee Undisputed 01/23/2026 1116279713 CMS
GlaxoSmithKline, LLC. $3,250.00 05/29/2024 Consulting Fee Undisputed 01/23/2026 1115908518 CMS
GlaxoSmithKline, LLC. $1,950.00 08/16/2024 Consulting Fee Undisputed 01/23/2026 1116383340 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.